

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2024 Defense Health Agency **Date:** March 2023

Appropriation/Budget Activity 0130: <i>Defense Health Program I BA 2: RDT&E</i>					R-1 Program Element (Number/Name) PE 0607100DHA I <i>Medical Products and Capabilities Enhancement Activities</i>							
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
Total Program Element	49.174	16.976	17.971	18.330	0.000	18.330	18.697	19.071	19.452	19.841	Continuing	Continuing
377A: <i>GDF-Medical Products and Capabilities Enhancement Activities</i>	49.174	16.976	17.971	18.330	0.000	18.330	18.697	19.071	19.452	19.841	Continuing	Continuing

Note

N/A

A. Mission Description and Budget Item Justification

Guidance for Development of the Force-Medical Products and Capabilities Enhancement Activities: Funds will support developmental upgrades to medical systems, training systems, and products that have been fielded, are routinely used in a fixed facility, or that have been approved for full-rate production and for which procurement funding is anticipated in the current fiscal year or subsequent fiscal years. These funds will support testing and evaluation for the enhancement of fielded or procured medical systems/products and medically-related information technology systems, assessment of fielded medical products or medical practices in order to identify the need/opportunity for changes, and analyses of clinical intervention outcomes to enhance and improve indications for pharmaceutical products. Efforts address the Military Health System Concept of Operations documents and follow-on Capabilities Based Assessments/Joint Capability Documents, appropriate Component requirements, legislative and Executive directives, and others as appropriate. Coordination occurs through the planning and execution activities of the Defense Health Agency Component Acquisition Executive (DHA CAE).

B. Program Change Summary (\$ in Millions)

	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total
Previous President's Budget	17.619	17.971	18.330	-	18.330
Current President's Budget	16.976	17.971	18.330	-	18.330
Total Adjustments	-0.643	0.000	0.000	-	0.000
• Congressional General Reductions	-	-			
• Congressional Directed Reductions	-	-			
• Congressional Rescissions	-	-			
• Congressional Adds	-	-			
• Congressional Directed Transfers	-	-			
• Reprogrammings	-	-			
• SBIR/STTR Transfer	-0.643	-			

Change Summary Explanation

N/A

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2024 Defense Health Agency										Date: March 2023		
Appropriation/Budget Activity 0130 / 2					R-1 Program Element (Number/Name) PE 0607100DHA / Medical Products and Capabilities Enhancement Activities				Project (Number/Name) 377A / GDF-Medical Products and Capabilities Enhancement Activities			
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
377A: GDF-Medical Products and Capabilities Enhancement Activities	49.174	16.976	17.971	18.330	0.000	18.330	18.697	19.071	19.452	19.841	Continuing	Continuing

A. Mission Description and Budget Item Justification

Guidance for Medical Products and Capabilities Enhancement Activity: This funding supports enhancement of existing medical products and medically related information technology systems to further fielding of joint medical materiel capabilities to meet Warfighter needs through support testing and evaluation for the enhancement of fielded or procured medical systems/products and medically-related information technology systems, assessment of fielded medical products or medical practices in order to identify the need/opportunity for changes, and analyses of clinical intervention outcomes to enhance and improve indications for pharmaceutical products.

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total
Title: 377A: GDF – Medical Products and Capabilities Enhancement Activities	16.976	17.971	18.330	0.000	18.330
Description: This funding provides support for developmental efforts to upgrade medical products and capabilities that have been fielded or have received approval for full rate production and anticipate production funding in the current or subsequent fiscal year. These funds will support testing and evaluation for the enhancement of fielded or procured medical systems/products and medically-related information technology systems, assessment of fielded medical products or medical practices in order to identify the need/opportunity for changes, and analyses of clinical intervention outcomes to enhance and improve indications for pharmaceutical products.					
FY 2023 Plans: Funding will modernize and upgrade products through joint testing and evaluation to improve fielding of medical materiel products. The Adenovirus Vaccine – Modernized Production program seeks to continue to modernize manufacturing capability of the only FDA-approved febrile acute respiratory disease (ARD) preventative vaccine for military recruits. In FY23, the program will optimize a closed system for bulk virus manufacturing, establish a secondary source for manufacturing the bulk virus, develop equipment, and transfer test methods for drug product and cleaning validation. Brain Hemorrhage Detector Modernization program seeks to modernize a US FDA approved, brain hemorrhage detection capability. In FY23, the program will build, test, and produce 20 devices for first article test/military validation. Additionally, funding will support a number of other programs to					

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2024 Defense Health Agency		Date: March 2023
Appropriation/Budget Activity 0130 / 2	R-1 Program Element (Number/Name) PE 0607100DHA / <i>Medical Products and Capabilities Enhancement Activities</i>	Project (Number/Name) 377A / <i>GDF-Medical Products and Capabilities Enhancement Activities</i>

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total
include Wound Healing Combat Gauze, Environmental Sentinel Biomonitor (ESB) - Develop Integrated System, as well as others. FY 2024 Base Plans: FY 2024 plans continue efforts outlined in FY2023 and Implement the necessary improvements and modernization in current manufacturing operations to ensure sustainability and continuity of supply for Military use of the Adenovirus Vaccine. FY 2024 OCO Plans: N/A FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to inflation program growth.					
Accomplishments/Planned Programs Subtotals	16.976	17.971	18.330	0.000	18.330

C. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

N/A

D. Acquisition Strategy

This program will integrate product improvements and enhancements resulting from post marketing studies and surveillance in existing medical products and medically related information technology systems to better meet Warfighter needs.